共查询到20条相似文献,搜索用时 31 毫秒
1.
Yoda S Soejima K Yasuda H Naoki K Kawada I Watanabe H Nakachi I Satomi R Nakayama S Ikemura S Terai H Sato T Morosawa M Asano K 《Cancer chemotherapy and pharmacology》2011,67(3):717-722
Background
This phase I study was conducted to evaluate the feasibility and to determine the recommended doses of the combination therapy of S-1 and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC) as second-line treatment.Methods
Patients with NSCLC who were previously treated with one chemotherapy regimen and had a performance status of 0 or 1 were eligible. CPT-11 was administered at 60 mg/m2 (level 1), 80 mg/m2 (level 2) on days 1 and 8, and oral S-1 was administered at 80 mg/day for body surface area (BSA) less than 1.25 m2, 100 mg/day for BSA 1.25–1.5 m2, and 120 mg/day for BSA more than 1.5 m2 on days 1–14 every 3 weeks. The dose-limiting toxicity (DLT) was defined as grade 4 leukocytopenia or neutropenia, grade ≥3 neutropenia with fever over 38°C, grade ≥3 thrombocytopenia, or grade ≥3 major nonhematological toxicities.Results
Nine patients were enrolled in the study. None of 3 patients enrolled in level 1 had any DLT. Of 6 patients in level 2, 2 patients had grade 3 diarrhea and one had grade 3 interstitial pneumonia. Level 1 was declared as the recommended dose.Conclusion
The feasibility of the combination therapy of S-1 and CPT-11 was shown in the second-line setting for the treatment of advanced NSCLC. The recommended dose of CPT-11 was 60 mg/m2 combined with standard dose of S-1 for phase II trials of pretreated advanced NSCLC patients. 相似文献2.
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer
Hitoshi Wada Kenji Nemoto Takuma Nomiya Misako Murakami Motohisa Suzuki Yuuki Kuroda Mayumi Ichikawa Ibuki Ota Yasuhito Hagiwara Hisanori Ariga Ken Takeda Kenji Takai Keisuke Fujimoto Masahiro Kenjo Kazuhiko Ogawa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2013,18(2):273-278
Background
The purpose of this phase I trial of S-1 chemotherapy in combination with pelvic radiotherapy for locally recurrent rectal cancer was to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicity (DLT) of S-1.Methods
We enrolled 9 patients between April 2005 and March 2009. Radiotherapy (total dose, 60 Gy in 30 fractions) was given to the gross local recurrent tumor and pelvic nodal metastases using three-dimensional radiotherapy planning. We administered oral S-1 twice a day on days 1–14 and 22–35 during radiotherapy. The dose of S-1 was initially 60 mg/m2/day and was increased to determine the MTD and RD for this regimen.Results
DLT appeared at dose level 2 (70 mg/m2/day) in 2 patients, who experienced grade 3 enterocolitis and consequently required suspension of S-1 administration for longer than 2 weeks. Hematological toxicity was mild and reversible. At the initial evaluation, complete regression and partial regression were seen in 1 patient (11%) and 2 patients (22%), respectively.Conclusion
This phase I trial of S-1 chemotherapy with pelvic radiotherapy for locally recurrent rectal cancer revealed that the MTD for S-1 was 70 mg/m2/day and the RD was 60 mg/m2/day. 相似文献3.
Akira Ono Tateaki Naito Haruyasu Murakami Toshiaki Takahashi Yukiko Nakamura Asuka Tsuya Kyoichi Kaira Satoshi Igawa Takehiro Shukuya Akihiro Tamiya Rieko Kaira Masahiro Endo Nobuyuki Yamamoto 《International journal of clinical oncology / Japan Society of Clinical Oncology》2010,15(2):161-165
Background
No investigation of S-1 monotherapy in previously treated advanced non-small-cell lung cancer (NSCLC) patients has yet been reported. We conducted a retrospective study to evaluate the efficacy and tolerability of S-1 in patients with failure of second- or further-line chemotherapy.Patients and methods
The records of NSCLC patients who had received S-1 monotherapy between January 2005 and November 2006 with the following eligibility criteria were reviewed: previously treated with at least two regimens including platinum and docetaxel in the case of nonadenocarcinoma patients, and including platinum, docetaxel and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in the case of adenocarcinoma patients. S-1 was administered for 28 consecutive days, followed by a 14-day drug-free period (42 days in one course). The drug was administered in two divided doses daily at 80 mg/day for patients with a body surface area <1.25 m2, 100 mg/day for those with a body surface area of 1.25–1.5 m2, and 120 mg/day for those with a body surface area ≥1.5 m2.Results
Thirty-five patients were registered. The median number of courses administered per patient was 2 (range 1–9). The toxicity profile was mild, and grade 3 or more severe toxicity was rare. The overall response and disease control rates were 5.7% and 40%, respectively. The median survival time was 208 days.Conclusion
S-1 exhibits modest activity and acceptable toxicity when used as a third or subsequent line of chemotherapy in patients with advanced NSCLC. 相似文献4.
Hidemi Kiyota Isamu Okamoto Masayuki Takeda Haruko Daga Tateaki Naito Masaki Miyazaki Hideaki Okada Hidetoshi Hayashi Kaoru Tanaka Masaaki Terashima Koichi Azuma Haruyasu Murakami Koji Takeda Nobuyuki Yamamoto Kazuhiko Nakagawa 《Cancer chemotherapy and pharmacology》2013,71(4):859-865
Background
A phase I dose-escalation study was performed to investigate the safety and pharmacokinetics of the combination of S-1 and gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.Methods
Patients received gefitinib at a fixed daily oral dose of 250 mg, and S-1 was administered on days 1–14 every 21 days at doses starting at 60 mg/m2 (level 1) and escalating to 80 mg/m2 (level 2). The primary end point of the study was determination of the recommended dose for S-1 given in combination with a fixed dose of gefitinib.Results
Twenty patients were enrolled in the study. Two of the first six patients at dose level 2 experienced a dose-limiting toxicity (elevation of alkaline phosphatase of grade 3 in one patient; elevations of aspartate and alanine aminotransferases of grade 3 in the other). The recommended dose was thus determined as level 2, and an additional 11 patients were assigned to this level. All observed adverse events were well managed. The response rate was 50 % (10 of 20 patients), and the median progression-free survival (PFS) and overall survival times were 10.5 and 21.2 months, respectively. In EGFR mutation–positive patients (n = 9), seven patients achieved an objective response and the median PFS was 12.4 months, whereas none with wild-type EGFR (n = 6) responded. No pharmacokinetic interaction between S-1 and gefitinib was detected.Conclusions
The combination of S-1 and gefitinib is well tolerated and appears to possess activity against EGFR mutation–positive NSCLC. 相似文献5.
Masaichi Ogawa Michiaki Watanabe Tetsuya Kobayashi Ken Eto Akihiro Oda Tadashi Anan Takenori Hayashi Yoshinobu Mitsuyama Katsuhiko Yanaga 《International journal of clinical oncology / Japan Society of Clinical Oncology》2013,18(4):678-683
Background
We evaluated the safety, efficacy, and compliance of 1-year treatment with S-1 in patients with stage II/III resectable colorectal cancer.Methods
S-1 was administered orally in two divided doses daily. The dose was assigned according to body surface area (BSA) as follows: BSA <1.25 m2, 80 mg/day; BSA ≥1.25 to <1.5 m2, 100 mg/day; and BSA ≥1.5 m2, 120 mg/day. S-1 was given for 28 consecutive days, followed by a 14-day rest. The study objects were the rate of completion of treatment as planned at 1 year, the ratio of the actually administered dose to the planned dose at 1 year, and the total number of days of treatment.Results
At 1 year, the rate of completion of treatment as planned was 77.7 % (42/54 patients), and the ratio of the actually administered dose to the planned dose was 82.9 %. The mean and median total numbers of days of treatment were 209 and 252, respectively. Grade 3 or higher toxicity (watery eyes) occurred in only 1 patient.Conclusion
S-1 adjuvant chemotherapy had acceptable compliance, safety, and efficacy in patients with colorectal cancer. S-1 adjuvant chemotherapy is considered a possible standard treatment regimen for colorectal cancer. 相似文献6.
Inkeun Park Jae-Lyun Lee Min-Hee Ryu Heung Moon Chang Tae-Won Kim Sun-Jin Sym Sung Sook Lee Geundoo Jang Changhoon Yoo Kyun-Seop Bae Yoon-Koo Kang 《Cancer chemotherapy and pharmacology》2010,65(3):473-480
Background
We aimed to determine the maximum-tolerated dose (MTD) of S-1 when given with oxaliplatin, to evaluate S-1 pharmacokinetics, and to determine the efficacy and safety of this regimen as a first-line treatment for advanced gastric cancer (AGC).Methods
Oxaliplatin was fixed at a dose of 130 mg/m2 on day 1 (D1). S-1 was administered from D1 to D14 of a 3-week cycle, and escalated by 10 mg/m2 per day from 70 mg/m2 per day up to 100 mg/m2 per day. Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle.Results
In phase I (n = 18), MTD was not defined. In phase II (n = 47) with the planned maximum dose, partial response was achieved in 26 patients (55.3%) and stable disease in 14 patients (29.8%). The median time to progression was 6.6 months (95% CI 4.0–9.2 months) and the median overall survival was 12.5 months (95% CI 9.2–15.9 months). Frequent grade 3/4 toxicities included thrombocytopenia (39%), neutropenia (28%), anemia (17%), and leukopenia (13%). There was one grade 5 febrile neutropenia during the first cycle.Conclusions
The pharmacokinetics of S-1 was not influenced by oxaliplatin. S-1/Oxaliplatin combination therapy is highly active against AGC and has a favorable toxicity profile. 相似文献7.
S. Fushida J. Kinoshita M. Kaji Y. Hirono F. Goda Y. Yagi K. Oyama Y. Sudo Y. Watanabe T. Fujimura 《Cancer chemotherapy and pharmacology》2013,71(5):1265-1272
Purpose
We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC).Methods
Patients with PC confirmed by laparoscopy or laparotomy received IP docetaxel on days 1 and 15 and S-1 (80 mg/m2) on days 1–14 every 4 weeks.Results
In the phase I part (n = 12), each cohort received escalating doses of docetaxel (35–50 mg/m2); the MTD was determined to be 50 mg/m2 and the RD was determined to be 45 mg/m2. Dose-limiting toxicities included grade 3 febrile neutropenia and grade 3 diarrhea. In the phase II part (n = 27), the median number of courses was 4 (range 2–11). The 1-year overall survival (OS) rate was 70 % (95 % confidence interval 53–87 %). The overall response rate was 22 % and peritoneal cytology turned negative in 18 of 22 (81 %) patients. The most frequent grade 3/4 toxicities included anorexia (19 %), neutropenia (7 %), and leukopenia (7 %).Conclusion
IP docetaxel plus S-1 is active and safety in gastric cancer patients with PC. 相似文献8.
Sook Ryun Park Yong Sang Hong Hyeong-Seok Lim Moon-Woo Seong Sun-Young Kong Sun Young Kim Young-Iee Park Kyung Hae Jung 《Cancer chemotherapy and pharmacology》2013,72(5):953-964
Purpose
We conducted a phase I study of S-1 combined with irinotecan and oxaliplatin (TIROX) to determine the maximum-tolerated dose (MTD) and recommended dose (RD) and to assess its safety, pharmacokinetics, pharmacogenetics, and preliminary efficacy in patients with metastatic colorectal cancer (MCRC) or metastatic gastric cancer (MGC).Methods
Patients received escalating doses of S-1 (30–40 mg/m2 b.i.d.) orally on days 1–14, an escalating dose of intravenous irinotecan (120–150 mg/m2) on day 1, and a fixed dose of intravenous oxaliplatin (85 mg/m2) on day 1 every 3 weeks.Results
Twenty-three patients (10 MCRC, 13 MGC; 13 chemonaive, 10 previously treated for metastatic disease) were treated across six dose levels. Because only one patient experienced a dose-limiting toxicity of grade 3 anorexia at the highest dose level (S-1 40 mg/m2 b.i.d., irinotecan 150 mg/m2, and oxaliplatin 85 mg/m2) (n = 8), the MTD was not obtained, and this level was established as the RD. With a median of 10 cycles per patient, the most common grade 3 or 4 adverse events included neutropenia (43 %), diarrhea (13 %), and nausea (13 %). In 22 efficacy-evaluable patients, the objective tumor response rate was 59.1 % (75 % for both MCRC and MGC in the first-line setting) and the disease control rate was 100 %. The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur).Conclusions
The new triplet TIROX regimen has shown promising antitumor activity and a favorable toxicity profile in patients with MCRC and MGC. 相似文献9.
Yousuke Nakai Hiroyuki Isayama Kei Saito Takashi Sasaki Naminatsu Takahara Tsuyoshi Hamada Suguru Mizuno Koji Miyabayashi Keisuke Yamamoto Dai Mohri Hirofumi Kogure Natsuyo Yamamoto Kenji Hirano Hideaki Ijichi Keisuke Tateishi Minoru Tada Kazuhiko Koike 《Cancer chemotherapy and pharmacology》2014,74(5):911-915
Purpose
In our previous randomized controlled trial, the addition of S-1 to gemcitabine for advanced pancreatic cancer did not prolong overall survival (OS) significantly, despite its higher response rate and longer progression-free survival (PFS). Leucovorin is known to enhance efficacy of S-1, and we conducted this phase I trial of combination therapy of gemcitabine, S-1 and leucovorin (GSL).Methods
Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study. Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m2 over 30 min on day 1, and oral S-1 at a dose of 40 mg/m2 twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1–7, every 2 weeks. A standard “3 + 3” phase I dose escalation design was utilized.Results
Fifteen patients were enrolled across three dose levels. Three patients developed DLTs: two patients in level 1 (grade 3 anorexia in 1 and grade 3 anorexia, stomatitis and diarrhea in 1) and one patient in level 2 (grade 3 deep vein thrombosis). No DLT was observed in level 3. Response rate and the disease control rate were 33 and 93 %, respectively. The median PFS and OS were 5.4 and 16.6 months. Ten of 12 patients (83 %) with elevated CA19-9 at baseline had a ≥50 % decline.Conclusions
RD of gemcitabine in GSL was determined as 1,000 mg/m2. GSL was well tolerable and showed promising results in advanced pancreatic cancer. 相似文献10.
Hida N Okamoto H Misumi Y Sato A Ishii M Kashizaki F Shimokawa T Shimizu T Watanabe K 《Cancer chemotherapy and pharmacology》2012,69(6):1625-1631
Purpose
This study aimed to establish the maximum tolerated dose of concurrent chemoradiotherapy (cCRT) with conventional administration of the docetaxel (D) plus cisplatin (P) (conv-DP) regimen.Methods
Patients (aged ≤70 years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) and having performance status 0 or 1 and adequate organ function were eligible. They received radiotherapy (60 Gy in 30 fractions) once daily starting on day 2. Concurrent P (day 1; 60 mg/m2 at Levels 1–3, 80 mg/m2 at Level 4) and D (day 1; 30 mg/m2 at Level 1, 40 mg/m2 at Level 2, 50 mg/m2 at Levels 3–4) were administered every 4 weeks for 2–4 courses.Results
Eighteen patients were enrolled (stage IIIA/IIIB, 5/13 patients). Three cases of dose-limiting toxicity were observed in this study, although another 3 cases were added at Levels 2 and 3. Radiotherapy was completed in 15 patients. Seventeen patients received more than 2 courses of chemotherapy. Neither Grade 3/4 esophagitis nor severe hematological events were observed at Levels 1–4. However, dose escalation to Level 5 (P [80 mg/m2], D [60 mg/m2]) was stopped because the Level 5 dose was the recommended dose (RD) of chemotherapy alone for stage IIIB/IV NSCLC in Japan. Therefore, the RD was determined as D50/P80 mg/m2 in this cCRT. The objective response rate was 89 %, and the median survival time was 23.6 months.Conclusions
cCRT with non-split DP was a tolerable and effective regimen, and RD was 50/80 mg/m2 every 4 weeks. 相似文献11.
Noboru Yamamoto Tomohide Tamura Takayasu Kurata Nobuyuki Yamamoto Ikuo Sekine Hideo Kunitoh Yuichiro Ohe Nagahiro Saijo 《Cancer chemotherapy and pharmacology》2009,65(1):79-88
Purpose
Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients.Methods
Patients ≥70 years were stratified into two groups based on renal functions: Group A, Ccr ≥ 60 and Group B, 40 ≤ Ccr < 60. The initial doses were 80 and 60 mg/m2 in Groups A and B, respectively. The doses were escalated in 20-mg/m2 increments to 100 mg/m2 until DLT.Results
Chemotherapy-naïve 39 elderly patients (Group A/Group B: 22/17) received a total of 83 cycles. Major toxicities were hematological. In Group A, one of the 15 patients at 100 mg/m2 experienced DLT (neutropenia) and the recommended dose was determined at 100 mg/m2. In Group B, three of the five patients had DLTs (leukopenia, neutropenia, thrombocytopenia and febrile neutropenia) at 100 mg/m2, and the recommended dose was determined at 80 mg/m2. The percentage decreases of neutrophil were well correlated with total and free-Pt AUCs. Partial responses were observed in 13 (33%) of the 39 patients, and 12 of the 13 patients who responded had a squamous cell carcinoma.Conclusions
Nedaplatin was administered simply and feasibly by stratifying renal function and exerted favorable antitumor activity for elderly patients with NSCLC, especially on squamous cell carcinoma. 相似文献12.
Zacharenia Saridaki Periklis Pappas John Souglakos Martha Nikolaidou Nikolaos Vardakis Athanasios Kotsakis Marios Marselos Vassilis Georgoulias Dimitris Mavroudis 《Cancer chemotherapy and pharmacology》2009,65(1):121-128
Purpose
To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of the paclitaxel, gemcitabine, oxaliplatin combination administered biweekly in patients with advanced solid tumors.Patients and methods
Patients received escalated doses of paclitaxel (starting dose: 100 mg/m2), gemcitabine (starting dose: 800 mg/m2) and oxaliplatin (starting dose: 50 mg/m2) on days 1 and 15 in cycles of every 4 weeks. DLTs were evaluated during the first cycle.Results
Twenty-seven patients (median age 65 years) with performance status 0–1 were treated on six dose escalation levels. Eleven patients (40.7%) were chemotherapy naïve, six (22.2%) had received 1 prior chemotherapy regimen and ten (37.1%) 2 or more. The DLT level was reached at the doses of paclitaxel 110 mg/m2, gemcitabine 1,150 mg/m2 and LOHP 70 mg/m2. The dose-limiting events were grade 4 neutropenia and grade 3 febrile neutropenia. Neutropenia was the most common adverse event. A median of 3 cycles per patient was administered. One complete and five partial responses were observed in patients with ovarian carcinoma, NSCLC, urothelial cancer, mesothelioma and cancer of unknown primary. No pharmacokinetic drug interactions were detected.Conclusions
The recommended doses for future phase II studies of this combination are paclitaxel 110 mg/m2, gemcitabine 1,000 mg/m2 and oxaliplatin 70 mg/m2 every 2 weeks. The regimen is generally well tolerated and merits further evaluation. 相似文献13.
Markus Moehler Rolf Mahlberg Volker Heinemann Radka Obermannová Eugen Kubala Bohuslav Melichar Arndt Weinmann Paul Scigalla Marietta Tesařová Petr Janda Fabienne Hédouin-Biville Wasat Mansoor 《Gastric cancer》2017,20(2):358-367
Background
This phase I study investigated the safety and the maximum tolerated dose (MTD) of the oral fluoropyrimidine S-1 when combined with epirubicin and oxaliplatin (EOS).Methods
Patients aged ≥18 years with advanced or metastatic solid tumors were enrolled in a 3 + 3 design with S-1 dose escalation (two planned cohorts) performed according to the occurrence of dose-limiting toxicity (DLT). On day 1 of each 21-day cycle, patients received epirubicin 50 mg/m2 followed by oxaliplatin 130 mg/m2 (maximum 8 cycles) and then S-1 [20 mg/m2 (cohort 1) or 25 mg/m2 (cohort 2), twice daily]: first dose, evening of day 1; subsequent administration on days 2–14, twice daily; last dose, morning of day 15 (unlimited number of S-1 cycles). After protocol amendment, enrollment in a third cohort was restricted to patients with chemotherapy-naïve advanced or metastatic esophagogastric cancer.Results
DLT was reported for two of the five patients in cohort 2, defining 20 mg/m2 twice daily as the MTD of S-1 combined with epirubicin and oxaliplatin in heavily pretreated patients. Thirteen patients with chemotherapy-naïve advanced or metastatic esophagogastric cancer were subsequently enrolled and treated at an S-1 dose level of 25 mg/m2 twice daily; no DLTs were reported; median overall survival was 13.1 months. Of the 11 evaluable patients, three (27 %) had partial responses and seven (64 %) had stable disease. The safety profile was in line with expectations.Conclusions
The promising activity of EOS (S-1 dose level, 25 mg/m2 twice daily) and acceptable safety profile support further clinical development of this combination for the first-line treatment of patients with advanced or metastatic esophagogastric cancer.14.
Nariaki Tomiyama Muneaki Hidaka Hideo Hidaka Yukihiro Kawano Norihisa Hanada Hideki Kawaguchi Kazuhiko Arimori Chizuko Nakamura 《Cancer chemotherapy and pharmacology》2010,65(4):807-809
Purpose
The safety and efficacy of S-1 in hemodialysis patients have not been established. We evaluated the safety and efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.Patient
A 66-year-old Japanese man with chronic renal failure, who had undergone hemodialysis three times a week for 3 years. Based on the diagnosis of stage IV gastric cancer, S-1 therapy was started. S-1 was administered 11 times at a daily dose of 23.5 mg/m2 (40 mg/body) after hemodialysis, followed by a rest. One course was a period of 28 days. Blood samples were obtained after the first administration of S-1 and before beginning the fourth course. The concentration of 5-FU was determined by high-performance liquid chromatography.Results
Area under the concentration–time curve (AUC) of 5-FU was 2647.2 ng h/mL after administration of S-1 of 23.5 mg/m2 (40 mg/body). During the S-1 treatment, serious adverse events such as neutropenia were not observed; however, decreases in hemoglobin level were observed (grade 3). The treatment was well tolerated. After the second course of chemotherapy, the primary lesion showed a partial response and lymph node metastases and liver metastases showed stable disease.Conclusions
Our results suggest that S-1 is an important treatment option for patients with hemodialysis with advanced gastric cancer. 相似文献15.
Hidetoshi Eguchi Hiroaki Nagano Shogo Kobayashi Koichi Kawamoto Hiroshi Wada Naoki Hama Yoshito Tomimaru Hirofumi Akita Daisuke Sakai Taroh Satoh Toshihiro Kudo Fumiaki Isohashi Masaki Mori Yuichiro Doki 《Cancer chemotherapy and pharmacology》2014,73(2):309-315
Purpose
Use of the fourth-generation oral fluoropyrimidine S-1 together with gemcitabine has shown striking anticancer effects. In this single-arm phase I trial of preoperative combination therapy using gemcitabine and S-1 concurrently with radiotherapy, we verified the safety and feasibility and determined the maximum-tolerated dose of each drug in patients with resectable pancreatic cancer.Methods
A standard 3+3 dose escalation scheme was used. Patients with cytologically or histologically proven resectable pancreatic ductal adenocarcinoma were administered 30-min intravenous gemcitabine infusions on days 1, 8, 22, and 29 and S-1 orally on days 1–5, 8–12, 22–26, and 29–33. A total radiation dose of 50.4 Gy (1.8 Gy/day, 5 times per week, 28 fractions) was concurrently delivered. Surgical exploration was scheduled 4–7 weeks after the final radiation fraction.Results
Twenty-one patients were enrolled. No treatment-related deaths occurred during this study. Recommended doses were determined to be 80 mg/m2 of S-1 daily and 1,000 mg/m2 of gemcitabine. CA19-9 was reduced to <50 % of baseline values in 12 (75 %) of 16 measurable patients. Nineteen of 21 enrolled patients successfully underwent surgical resection.Conclusions
Preoperative chemoradiotherapy consisting of gemcitabine and S-1 concurrent with full-dose radiation is feasible and well tolerated. 相似文献16.
Manabu Shiozawa Makoto Akaike Nobuhiro Sugano Kazuhito Tsuchida Naoto Yamamoto Soichiro Morinaga 《Cancer chemotherapy and pharmacology》2010,66(5):987-992
Purpose
A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer. The aim of this study was to determine the efficacy and safety of combining irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.Methods
Irinotecan was administered as an intravenous infusion at a dose of 120 mg/m2 on day 1 and 15. And S-1 was administered orally on days 1–14 of a 28-day cycle. S-1 was given orally at a dose that did not exceed 40 mg/m2 based BSA: BSA < 1.25 m2, 40 mg twice daily; 1.25–1.5 m2, 50 mg twice daily, and BSA > 1.5 m2, 60 mg twice daily, for 14 consecutive days.Results
A total of 38 patients were enrolled. An intent-to-treat analysis showed a complete response and partial response to occur in 13.2% and 50.0%, respectively. The disease control rate was 84.2%. The median progression-free survival and overall survival were 10.0 months and 29.1 months, respectively. The rates of grade 3/4 toxicity over 4 cycles were the following: neutropenia, 15.8%; leucopenia, 7.9%; anorexia, 15.8%; diarrhea, 10.5%. Conclusion: IRIS is an effective, well tolerated and convenient treatment regimen for patients with advanced colorectal cancer. 相似文献17.
D. Ross Camidge Normand Blais Derek J. Jonker Denis Soulières Robert C. Doebele Ana Ruiz-Garcia Aron Thall Ke Zhang Scott A. Laurie Richard C. Chao Laura Q. Chow 《Cancer chemotherapy and pharmacology》2013,71(2):307-319
Purpose
To determine the maximum tolerated dose (MTD), safety and tolerability of sunitinib plus pemetrexed and cisplatin for advanced solid malignancies.Methods
Using a 3 + 3 dose-escalation design, patients received oral sunitinib (37.5 or 50 mg) qd on a continuous daily dosing (CDD) schedule or Schedule 2/1 (2 weeks on, 1 week off treatment) plus pemetrexed (400 or 500 mg/m2 IV) and cisplatin (75 mg/m2 IV) q3w up to 6 cycles.Results
Sunitinib 37.5 mg/pemetrexed 400 mg/m2/cisplatin 75 mg/m2 CDD (n = 5) was not tolerated. Lower doses on this schedule were not explored. The Schedule 2/1 MTD (n = 15) was sunitinib 37.5 mg/pemetrexed 500 mg/m2/cisplatin 75 mg/m2, based on one dose-limiting toxicity (myocardial infarction) out of six patients. The MTD was further studied in an expansion cohort of 10 non-small cell lung cancer (NSCLC) patients and one mesothelioma patient. There were no clinically significant drug–drug interactions. Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin. Four of eight NSCLC patients in the dose-escalation and expansion cohorts at the Schedule 2/1 MTD who were evaluable for efficacy had stable disease ≥8 weeks, and the one patient with mesothelioma had a partial response.Conclusions
In patients with advanced solid malignancies, sunitinib was not tolerated at 37.5 mg CDD with standard pemetrexed and cisplatin doses. Dose reductions were often needed due to cumulative myelosuppression following cycle 1. The MTD showed modest antitumor activity. 相似文献18.
Norisuke Nakayama Kenji Ishido Keisho Chin Ken Nishimura Mizutomo Azuma Satoshi Matsusaka Yasuhiro Inokuchi Satoshi Tanabe Yosuke Kumekawa Wasaburo Koizumi 《Gastric cancer》2017,20(2):350-357
Background
In Japan, S-1, an oral fluoropyrimidine, plus cisplatin is a standard regimen for advanced gastric cancer, whereas nab-paclitaxel is a treatment option. We aimed to evaluate the tolerance, pharmacokinetics, safety, and clinical efficacy of S-1 combined with nab-paclitaxel in patients with advanced gastric cancer in a phase 1 study.Methods
The primary objective was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of S-1 plus nab-paclitaxel. The study was designed in accordance with a standard 3 + 3 method. Patients received 3-week cycles of treatment. S-1 was administered orally at 80 mg/m2 twice daily for 14 days, and nab-paclitaxel was administered as an intravenous infusion at 180, 220, or 260 mg/m2 on day 1 or 8.Results
Among the 16 patients enrolled, dose-limiting toxicity was observed in one patient at level 2a (S-1 80 mg/m2 twice daily plus nab-paclitaxel 220 mg/m2 on day 1). The MTD was not obtained, but the RD was established as level 3a (S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1). The most common grade 3–4 toxicity was neutropenia (62.5 %). The overall response rate was 54.5 %. The pharmacokinetic profiles of coadministered S-1 and paclitaxel were comparable to those of nab-paclitaxel or S-1 alone.Conclusions
Based on the present results, the RD was determined as level 3a (S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1). This combination therapy was well tolerated and showed antitumor efficacy in patients with advanced gastric cancer.19.
Hitoshi Kusaba Taito Esaki Junji Kishimoto Keita Uchino Shuji Arita Hozumi Kumagai Kenji Mitsugi Koichi Akashi Eishi Baba 《Cancer chemotherapy and pharmacology》2013,71(1):29-34
Purpose
The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer. However, the safety and efficacy of bevacizumab (BV) to combine with irinotecan and S-1 has not been determined. The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer.Methods
This study initially had been planned as a phase I/II study. Eighty mg/m2 of irinotecan on days 1 and 8, 80 mg/m2 of S-1 for 14 consecutive days, and two doses of BV (Level 1; 10 mg/kg, Level ?1; 7.5 mg/kg) were administered on day 1 every 3 weeks.Results
Fourteen patients were enrolled in phase I of the study between January 2008 and September 2010. Dose-limiting toxicities were diarrhea, abdominal pain, and infection. The MTD and RD of BV were determined to be 10 mg/kg and 7.5 mg/kg, respectively. The main adverse events were leukopenia, anorexia, and diarrhea. There were no treatment-related deaths. An independent review committee was scheduled to evaluate safety in phase I, but this trial closed early due to toxicity.Conclusions
This study identified the risk of gastrointestinal toxicity with the combination of irinotecan, S-1 and BV as second-line chemotherapy in patients with advanced colorectal cancer. 相似文献20.
Shogo Kobayashi Hiroaki Nagano Daisuke Sakai Hidetoshi Eguchi Etsuro Hatano Masashi Kanai Satoru Seo Kojiro Taura Yutaka Fujiwara Tetsuo Ajiki Shigekazu Takemura Shoji Kubo Hiroaki Yanagimoto Hideyoshi Toyokawa Akihito Tsuji Hiroaki Terajima Satoshi Morita Tatsuya Ioka 《Cancer chemotherapy and pharmacology》2014,74(4):699-709